Launched in October 2023, the Center for Respiratory Biology and Therapeutics brings together scientific research teams to build a transformative “bench to bedside and back” platform to drive the next phase of discoveries and novel therapeutics. We aim to improve care for children with respiratory disease and train the next generation of respiratory researchers.
The center provides the space, capabilities, and resources needed for clinical and bench investigators to come together to build a community that includes the full spectrum of respiratory research across Seattle Children’s.
Research Areas of Focus
The center focuses efforts on basic, translational, clinical, epidemiologic and global health research to develop and implement new respiratory therapies. Learn about our researchers on the Meet Our Members page.
- Cystic fibrosis
- Asthma
- Chronic lung disease of prematurity
- Congenital and acquired structural airway and lung diseases
- Acute and chronic respiratory failure
- Novel respiratory support technologies
- Novel technologies to deliver inhaled medications
- Sleep disordered breathing
- Primary ciliary dyskinesia
- Respiratory global health research
- Interstitial lung disease
- Pulmonary hypertension
- Respiratory quality improvement research
Leadership and Governance
Members of the CRBT Leadership Team meet monthly to discuss scientific strategy planning and governance for the center.
CRBT Researcher Meetings
All CRBT researchers are invited to attend quarterly meetings to provide their feedback on scientific strategic planning.
For more information regarding CRBT governance and CRBT researcher meetings, please send us an email us.
If you are currently a member of CRBT, please see the center’s page on CHILD for member resources.
Key Partnerships
Cystic Fibrosis Therapeutics Development Network
The Cystic Fibrosis Therapeutics Development Network (TDN) is the largest cystic fibrosis (CF) clinical trials network in the world, bringing together experts from across the country to evaluate the safety and effectiveness of new CF therapies through clinical studies. The TDN has supported over 150 industry- and investigator-initiated studies across more than 90 sites in the United States.
New therapies that have transformed the lives of patients with CF around the world have been advanced to the bedside and tested at Seattle Children’s through this partnership.
Drs. Nicole Hamblett and Christopher Goss serve as co-executive directors of Cystic Fibrosis Therapeutics Development Network Coordinating Center.